Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that causes inflammation of the optic nerve and the spinal cord.| Neuromyelitis News
Nearly all clinicians (88%) in a U.S. survey have prescribed approved NMOSD treatments for their patients with anti-AQP4 antibodies.| Neuromyelitis News
A discussion with fellow neuromyelitis optica patients prompts columnist Jennifer van Amerom to address her mental health symptoms.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
In patients treated with Enspryng, researchers found the proportions of B-cells was unchanged, suggesting it altered their characteristics.| Neuromyelitis News